AAMI ST67 2019
$75.64
ANSI/AAMI ST67:2019 – Sterilization of health care products-Requirements and guidance for selecting a sterility assurance level (SAL) for products labeled “sterile”
Published By | Publication Date | Number of Pages |
AAMI | 2019 | 41 |
This standard establishes requirements, guidance and a risk framework for identification of acceptable approach(es) for assurance of sterility and for selection of alternative SAL(s) or aseptic processing for health care product that cannot be terminally sterilized to achieve an SAL value of 10-6.
PDF Catalog
PDF Pages | PDF Title |
---|---|
1 | ANSI/AAMI ST67:2019; Sterilization of health care products—Requirements and guidance for selecting a sterility assurance level (SAL) for products labeled “sterile” |
3 | Title page |
4 | AAMI Standard Copyright information |
5 | Contents Page |
6 | Committee representation |
9 | Foreword |
10 | Introduction |
11 | 1 Scope 1.1 Inclusions 1.2 Exclusions 2 Normative references |
12 | 3 Definitions |
14 | 4 Determination of approach for assurance of sterility 4.1 General 4.2 Selection of a sterility assurance level, SAL 4.2.1 Intended use 4.2.2 Compatibility with an SAL value of 10-6 |
15 | Figure 1—Numerical values of sterility assurance level (SAL) together with the concept of assurance of sterility 4.2.3 Modification strategies to achieve an SAL value of 10-6 |
16 | 4.3 Risk assessment to determine acceptability of an approach to sterility assurance other than an SAL value of 10-6 |
17 | Figure 2—Flowchart for product to achieve an SAL value of 10-6 or alternate SAL (4.2.1) 4.3.1 Risk-based feasibility assessment |
18 | 4.3.2 Consideration of other approaches to assure sterility 5 Approaches to assure sterility other than use of an SAL value of 10-6 5.1 Selection of an alternative SAL |
19 | 5.2 Aseptic Processing |
20 | Annex A (informative) Background and historical application of sterility assurance A.1 Introduction A.2 History of sterility assurance |
21 | A.3 Explanation of terms SAL and PNSU Table A.1—Examples of historical SALs for terminally sterilized product* |
22 | Annex B (informative) Modification strategies to consider in order to achieve terminal sterilization at an SAL value of 10-6 B.1 Materials |
23 | B.2 Product and package design B.3 Method of sterilization establishment |
24 | B.4 Sterilization technology |
26 | B.5 Bioburden |
28 | Annex C (informative) Risk management considerations if an SAL value of 10-6 cannot be achieved C.1 General C.2 Criteria in determining if a modification is feasible |
29 | C.3 Selection of method for assurance of sterility C.4 Risk aspects to consider in determining if a modification is feasible |
30 | C.5 Risk aspects to consider for an individual patient |
31 | Table C.1—Risk aspects to consider for an individual patient: Example of severity rankings Figure C.1—Probability of infection resulting from three potential sources |
32 | Table C.2—Risk aspects to consider for an individual patient: Example of probability rankings Table C.3—Risk aspects to consider for an individual patient: Example of overall risk rankings |
33 | Annex D (informative) Examples of risk management considerations to select an approach to assure sterility D.1 General D.2 Examples of microbiological factors that might be associated with a risk analysis |
34 | D.3 Example 1—Biosynthetic skin dressing Table D.1—Assessment of product SAL requirements and practicability of 10-6 sterilization for biosynthetic skin dressing |
36 | D.4 Example 2—Porcine heart valve Table D.2—Assessment of product SAL requirements and practicability of 10-6 sterilization for porcine heart valve |
37 | D.5 Example 3—Drug with drug delivery device Table D.3—Assessment of product SAL requirements and practicability of 10-6 sterilization for drug with drug delivery device |
38 | D.6 Example 4—Ultrasonic tissue cutting device Table D.4—Assessment of product SAL requirements and practicability of 10-6 sterilization for ultrasonic cutting device |
39 | Bibliography |